LivaNova
LivaNova PLC is a publicly traded medical technology company that develops and sells neuromodulation and cardiopulmonary medical devices — including VNS Therapy, the aura6000 sleep apnea system, and the Essenz Perfusion System — to hospitals and healthcare providers in more than 100 countries.
- Company typePublic
- Founded2015
- HeadquartersLondon, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What LivaNova does
LivaNova PLC is a publicly traded medical technology company (NASDAQ: LIVN) headquartered in London, UK, formed in 2015 through the merger of Sorin Group (cardiopulmonary) and Cyberonics (neuromodulation). The company operates two business segments: Cardiopulmonary, anchored by the Essenz Perfusion System — the world's leading heart-lung machine, supported by oxygenators, cannulas, and related disposables used in cardiopulmonary bypass — and Neuromodulation, which includes VNS Therapy systems (Sentiva, SenTiva DUO, SYMMETRY) for drug-resistant epilepsy and difficult-to-treat depression, and the newly FDA-approved aura6000 System for obstructive sleep apnea.
The technical platform spans proprietary implantable pulse generators, hypoglossal nerve stimulation architectures, sensor-integrated perfusion hardware, and cloud-based digital health tools. Core intellectual property is protected by extensive US patent portfolios covering Sentiva, Inspire oxygenators, TandemLife/Protek Duo, S5, and Essenz systems. The OSPREY and RECOVER randomized controlled trials provide the clinical evidence base underlying both regulatory approvals and reimbursement decisions.
LivaNova generates revenue primarily through direct enterprise sales of capital equipment and implantable devices to hospitals and healthcare providers across more than 100 countries. FY2025 net revenue reached $1,388.1 million (10.7% YoY growth), with Cardiopulmonary contributing $785 million and Neuromodulation $152.7 million in Q4 2025. The company sells through its own field sales organizations and subsidiaries in the US, EU, China, Japan, Brazil, and other major markets. Reimbursement (notably a 48% Medicare increase for VNS Therapy effective January 2026) is a meaningful demand driver.
LivaNova firmographics
Firmographics- Name
- LivaNova
- Legal name
- LivaNova PLC
- Website
- https://livanova.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- LivaNova PLC is a publicly traded medical technology company that develops and sells neuromodulation and cardiopulmonary medical devices — including VNS Therapy, the aura6000 sleep apnea system, and the Essenz Perfusion System — to hospitals and healthcare providers in more than 100 countries.
- Ownership category
- akta.pro rank
LivaNova industry classification
Industry- Product category
- Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industries
- Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)
Keywords
Where LivaNova is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices15 records
Markets served
LivaNova business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Cardiopulmonary (Perfusion): Sales of cardiopulmonary equipment (Essenz Perfusion System, heart-lung machines), oxygenators, cannulas, and related disposables/consumables used during cardiac surgery. Full-year 2025 revenue of $785 million, up 13% year-over-year. Q4 2025 revenue of $206.6 million, up 13.7% year-over-year.
- Neuromodulation (Epilepsy, Depression, OSA): Sales of VNS Therapy systems (Sentiva/SenTiva DUO, SYMMETRY), the aura6000 System for OSA, and related implantable device components. Q4 2025 revenue of $152.7 million, up 11.0% year-over-year. Revenue driven by increased Medicare reimbursement for VNS Therapy (approximately 48% increase effective January 2026) and FDA approval of aura6000 System.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | VNS Therapy for drug-resistant epilepsy and difficult-to-treat depression; aura6000 System for obstructive sleep apnea; Essenz Perfusion System for cardiopulmonary bypass |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
LivaNova product offering
Product offeringCore offering
LivaNova is a global medical technology company that designs, manufactures, and sells advanced medical devices across two segments: Cardiopulmonary (capital equipment and consumables such as the Essenz Perfusion System, heart-lung machines, oxygenators, cannulas, and ECMO products) and Neuromodulation (implantable neurostimulation systems including VNS Therapy for drug-resistant epilepsy and difficult-to-treat depression, and the aura6000 hypoglossal nerve stimulation system for obstructive sleep apnea). Products are sold to hospitals and healthcare providers across 100+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- Essenz: Perfusion System for cardiopulmonary bypass procedures
- VNS Therapy
- SYMMETRY
- aura6000
- Sentiva
- TandemLife
- Protek Duo
- Inspire
- S5
Products and services
- Essenz Perfusion System Advanced heart-lung machine and perfusion management system used by perfusionists and cardiac surgeons during cardiopulmonary bypass procedures, providing real-time data monitoring and precision perfusion management.
Quantifiable outcome
- 65% responder rate at 12 months in OSPREY randomized controlled trial for obstructive sleep apnea with aura6000 System; increased to 84.5% with PolySync programming algorithm
- +6 more outcomes
Companies that use LivaNova
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
LivaNova technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
LivaNova partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Orrum Clinical AnalyticscoreOrrum Clinical Analytics and LivaNova entered a strategic partnership to integrate Orrum's CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System used during cardiopulmonary bypass procedures in cardiac surgery. The integration enables automatic, continuous data capture and transfer for post-operative analysis, peer benchmarking, and evidence-based performance improvement. The platform is built within a Patient Safety Organization recognized by the U.S. Department of Health & Human Services.
- Advanced Medical Technology Association (AdvaMed)minorAdvaMed advocates for patient access to safe, effective, and innovative medical technologies. LivaNova is an active member and participates in cybersecurity and information sharing working groups.
- Health Information Sharing and Analysis Center (H-ISAC)minorH-ISAC is a global, non-profit, member-driven organization offering healthcare stakeholders a trusted community for coordinating, collaborating, and sharing vital physical and cyber threat intelligence and best practices. LivaNova is an active member of this healthcare cybersecurity working group.
- Health Sector Coordinating Council (HSCC)minorHSCC serves as a public-private partnership focused on improving the resilience and security of the healthcare and public health sector. LivaNova participates in HSCC cybersecurity initiatives as part of its industry collaboration strategy.
- ALung Technologies Inc.coreLivaNova acquired 97% of Pittsburgh-based ALung Technologies Inc. in 2022, following ALung's FDA approval to market its artificial lung device. The deal included an initial payment of $10 million and potential milestone-based payments. ALung specializes in artificial lung devices (ECMO systems), complementing LivaNova's cardiopulmonary business.
Scale indicators25 records
Recent moves9 records
Expansion highlights5 records
LivaNova competitors and assessment
Company assessmentDirect peers
- Inspire Medical Systems: Inspire Medical Systems is the leading U.S. provider of hypoglossal nerve stimulation therapy for obstructive sleep apnea. It is the primary direct competitor to LivaNova's aura6000 System in the HGNS category, targeting the same CPAP-intolerant OSA patient population.
- Getinge: Getinge (including the legacy Maquet cardiopulmonary business) is one of LivaNova's closest competitors in heart-lung machines, oxygenators, and ECMO/cannula products. Both companies compete directly in the global cardiopulmonary perfusion equipment market, with overlapping product portfolios in cardiac surgery.
- Terumo: Terumo's cardiovascular division manufactures oxygenators, perfusion tubing, and cardiopulmonary bypass consumables that directly overlap with LivaNova's Inspire oxygenators and Essenz disposables. Both companies serve the same cardiac surgery customer base across global hospital systems.
- Edwards Lifesciences: Edwards Lifesciences is a leader in structural heart and critical care, with significant overlap in cardiac surgery products and monitoring. While its core is heart valves, its critical care monitoring products compete with parts of LivaNova's cardiopulmonary portfolio in the same surgical suites.
- ResMed: ResMed is the global leader in sleep-disordered breathing treatment, primarily CPAP devices for OSA. While it competes in the same therapeutic category as LivaNova's aura6000, it serves CPAP-responsive patients, making it both an adjacent player and a competitive constraint on the HGNS market opportunity.
Broad incumbents
- Medtronic: Medtronic is a diversified medical device leader with overlapping neuromodulation (deep brain stimulation, spinal cord stimulation), cardiac surgery, and cardiac rhythm management franchises. Its scale and R&D depth make it a broad incumbent that competes with LivaNova across multiple categories.
- Abbott: Abbott operates major cardiovascular and neuromodulation businesses (including post-St. Jude integration) that overlap with LivaNova's cardiac surgery and neurostimulation portfolios. As a broad incumbent, it competes with LivaNova in hospital accounts and electrophysiology/neurology procedure markets.
- Boston Scientific: Boston Scientific operates across interventional cardiology, cardiac surgery, peripheral interventions, and neuromodulation. While its neuromodulation focus is more chronic pain than VNS, it competes for hospital capital budgets and clinician mindshare across overlapping therapeutic areas.
- Philips: Philips has a significant Sleep & Respiratory business (CPAP, BiPAP, hospital ventilators) that overlaps with LivaNova's OSA adjacency and broader respiratory care. It is a broad incumbent in connected care and patient monitoring that competes with LivaNova's emerging digital health platform capabilities.
Emerging players
- Penumbra: Penumbra operates in interventional cardiology, vascular thrombectomy, and emerging neurovascular and immersive reality healthcare technologies. It has partial overlap with LivaNova in cardiac/neurovascular procedures and represents an emerging player expanding into adjacent device categories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LivaNova social profiles
Digital presenceLivaNova financial estimates
Financial estimateRevenue estimate
Valuation estimate
LivaNova leadership team
Management profileNumber of profiles
Profiles11 records
LivaNova subsidiaries and ownership
Company hierarchySubsidiaries21 records
LivaNova funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LivaNova M&A and investment
M&A and investmentM&A5 records
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LivaNova
What does LivaNova do?
LivaNova is a global medical technology company that designs, manufactures, and sells advanced medical devices across two segments: Cardiopulmonary (capital equipment and consumables such as the Essenz Perfusion System, heart-lung machines, oxygenators, cannulas, and ECMO products) and Neuromodulation (implantable neurostimulation systems including VNS Therapy for drug-resistant epilepsy and difficult-to-treat depression, and the aura6000 hypoglossal nerve stimulation system for obstructive sleep apnea). Products are sold to hospitals and healthcare providers across 100+ countries.
Is LivaNova a public or private company?
LivaNova is a public company. It is classified as public and is currently operating.
When was LivaNova founded?
LivaNova was founded in 2015. It employs 1,001 to 5,000 people.
Where is LivaNova based?
LivaNova is headquartered in London, United Kingdom, in the Europe region.
How does LivaNova make money?
Two revenue lines are on record. Cardiopulmonary (Perfusion) is the primary driver. The others are neuromodulation (Epilepsy, Depression, OSA).
Who are LivaNova's main competitors?
Direct peers on record are Inspire Medical Systems, Getinge, Terumo, Edwards Lifesciences and ResMed. Broad incumbents are Medtronic, Abbott, Boston Scientific and Philips. Penumbra is listed as an emerging player.
Does LivaNova have an API?
No public API is recorded for LivaNova.
What industry is LivaNova in?
LivaNova's product category is Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV). Its NAICS code is 334510 and its SIC code is 3845.